Charles Dunn

Charles Dunn has an extensive work experience in the field of investment and finance. Charles is currently working at SV Health Investors, where they started as an Investment Analyst in January 2018 and worked until December 2019. Charles then progressed to become an Investment Associate from December 2019 to December 2021, and further promoted to the role of Senior Investment Associate from December 2021 to December 2022. Currently, they hold the position of Vice President at SV Health Investors from December 2022.

In addition to their work at SV Health Investors, Charles has also worked as an Investor at various companies. Charles served as an Investor at Prilenia since March 2022, Quell Therapeutics since November 2021, Pulmocide since March 2020, Mestag Therapeutics since February 2020, Enara Bio since November 2020, Imbria Pharmaceuticals since September 2020, and Autifony Therapeutics since June 2019.

Before pursuing their career in investments, Charles had experience at Deloitte UK. Charles worked as an Associate (Entrepreneurial Business) from September 2014 to August 2015, Senior Associate (Entrepreneurial Business) from August 2015 to September 2016, and finally as an Assistant Manager from September 2016 to December 2017.

Overall, Charles Dunn's work experience showcases their expertise in investment analysis and management, along with their background in entrepreneurial business and consulting.

Charles Dunn attended UCL from 2009 to 2014, where they pursued an MSci in Human/Medical Genetics. Charles then went on to study at ICAEW from 2014 to 2017, earning an ACA degree. Prior to UCL, they attended Hills Road Sixth Form College from 2006 to 2008. No specific degree or field of study is mentioned for their time at Hills Road Sixth Form College.